Robert C. Malenka - 15 Apr 2026 Form 4 Insider Report for MapLight Therapeutics, Inc. (MPLT)

Reporting relationship: Director
Issuer ticker: MPLT
Reported as of: 15 Apr 2026
Net transaction value: -$231,152
SEC form: 4
Accepted by SEC: 17 Apr 2026, 16:05:06 UTC
Prior SEC filing: 24 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Kristopher L. Hanson, Attorney-in-Fact

Key filing fact

Robert C. Malenka filed Form 4 for MapLight Therapeutics, Inc. (MPLT) on 17 Apr 2026.

Key facts

This page summarizes Robert C. Malenka's Form 4 filing for MapLight Therapeutics, Inc. (MPLT).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 17 Apr 2026, 16:05.

Change

Previous filing in this sequence was filed on 24 Feb 2026.
Current net transaction value: -$231,152.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002021198 Primary reporting owner

Malenka Robert C.

Relationship: Director
Address: C/O MAPLIGHT THERAPEUTICS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY
Signature: /s/ Kristopher L. Hanson, Attorney-in-Fact
Signature date: 17 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MPLT transaction

Voting Common Stock

Sale

Transaction value: $231,152
Shares: -8,593
Change %: -2.6%
Price: $26.90
Shares after: 316,466
Date: 15 Apr 2026
Ownership: Direct
Footnotes: F1, F2

MPLT holding

Voting Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 31,672
Date: 15 Apr 2026
Ownership: See footnote
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 26, 2025.

Footnote F2

The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $26.35 to $27.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F3

The shares are held by the Robert C. Malenka Living Trust U/A DTD 08/21/2012, of which the Reporting Person is the sole trustee and has voting and dispositive power.